nefazodone has been researched along with 1-(3-chlorophenyl)piperazine in 17 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 12 (70.59) | 18.2507 |
| 2000's | 4 (23.53) | 29.6817 |
| 2010's | 1 (5.88) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Cleves, AE; Jain, AN; Kirshner, D; Langham, JJ; Spitzer, R | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Barbhaiya, RH; Behr, DA; Greene, DS; Natarajan, CS; Sainati, SM; Shukla, UA | 1 |
| Bernard, N; Cuisinaud, G; Ferry, N; Rougier, P; Sassard, J; Trepo, C | 1 |
| Barbhaiya, RH; Kaul, S; Shukla, UA | 1 |
| Barbhaiya, RH; Greene, DS; Shukla, UA | 2 |
| Barbhaiya, RH; Gammans, RR; Greene, DS; Marathe, PH; Mayol, RF; Pittman, KA; Robinson, D; Shukla, UA | 1 |
| Barbhaiya, RH; Brennan, J; Greene, DS; Marathe, PH; Salazar, DE; Shukla, UA | 1 |
| Barbhaiya, RH; Brady, ME; Greene, DS; Shukla, UA | 1 |
| Barbhaiya, RH; Buch, AB; Greene, DS | 1 |
| Shah, VR; Shyu, WC; Srinivas, NR; Yao, M | 1 |
| Caccia, S; Cervo, L; Fracasso, C; Guiso, G; Nacca, A | 1 |
| Granda, BW; Grassi, JM; Greenblatt, DJ; Harmatz, JS; Schmider, J; Shader, RI; von Moltke, LL | 1 |
| Srinivas, NR; Yao, M | 1 |
| Huang, MQ; Jemal, M; Mao, Y; Xia, YQ | 1 |
5 trial(s) available for nefazodone and 1-(3-chlorophenyl)piperazine
| Article | Year |
|---|---|
Influence of hepatic impairment on the pharmacokinetics of nefazodone and two of its metabolites after single and multiple oral doses.
Topics: Adolescent; Adult; Antidepressive Agents; Female; Humans; Liver Diseases; Male; Middle Aged; Piperazines; Triazoles | 1994 |
Lack of interaction between nefazodone and cimetidine: a steady state pharmacokinetic study in humans.
Topics: Administration, Oral; Adult; Analysis of Variance; Antidepressive Agents; Chromatography, High Pressure Liquid; Cimetidine; Cross-Over Studies; Drug Interactions; Histamine H2 Antagonists; Humans; Male; Piperazines; Serotonin Receptor Agonists; Triazoles | 1995 |
Safety, tolerance, and preliminary pharmacokinetics of nefazodone after administration of single and multiple oral doses to healthy adult male volunteers: a double-blind, phase I study.
Topics: Administration, Oral; Adult; Antidepressive Agents, Second-Generation; Double-Blind Method; Drug Administration Schedule; Drug Tolerance; Humans; Male; Middle Aged; Piperazines; Triazoles | 1995 |
Absorption and presystemic metabolism of nefazodone administered at different regions in the gastrointestinal tract of humans.
Topics: Adult; Antidepressive Agents, Second-Generation; Biological Availability; Chromatography, High Pressure Liquid; Cross-Over Studies; Digestive System; Humans; Intestinal Absorption; Intubation, Gastrointestinal; Male; Piperazines; Serotonin Receptor Agonists; Spectrophotometry, Ultraviolet; Triazoles | 1995 |
Single and multiple dose pharmacokinetics of nefazodone in subjects classified as extensive and poor metabolizers of dextromethorphan.
Topics: Adult; Antidepressive Agents, Second-Generation; Cytochrome P-450 CYP2D6; Dextromethorphan; Humans; Phenotype; Piperazines; Triazoles | 1996 |
12 other study(ies) available for nefazodone and 1-(3-chlorophenyl)piperazine
| Article | Year |
|---|---|
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Physical binding pocket induction for affinity prediction.
Topics: Binding Sites; Ligands; Models, Molecular; Neural Networks, Computer; Peptide Fragments; Protein Binding; Receptor, Serotonin, 5-HT1A | 2009 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Single- and multiple-dose pharmacokinetics of nefazodone in patients with hepatic cirrhosis.
Topics: Adult; Antidepressive Agents; Dose-Response Relationship, Drug; Female; Humans; Liver Cirrhosis; Male; Middle Aged; Piperazines; Serotonin Receptor Agonists; Triazoles | 1995 |
Nonlinear pharmacokinetics of nefazodone after escalating single and multiple oral doses.
Topics: Adult; Antidepressive Agents; Drug Administration Schedule; Half-Life; Humans; Male; Piperazines; Serotonin Receptor Agonists; Triazoles | 1995 |
Single-dose pharmacokinetics of nefazodone in healthy young and elderly subjects and in subjects with renal or hepatic impairment.
Topics: Administration, Oral; Adult; Age Factors; Aged; Antidepressive Agents; Female; Humans; Kidney Diseases; Liver Cirrhosis; Male; Middle Aged; Piperazines; Serotonin Receptor Agonists; Triazoles | 1995 |
Steady-state pharmacokinetics of nefazodone in subjects with normal and impaired renal function.
Topics: Antidepressive Agents; Female; Humans; Kidney Diseases; Male; Middle Aged; Piperazines; Serotonin Receptor Agonists; Triazoles | 1995 |
Sensitive liquid chromatographic-mass spectrometric assay for the simultaneous quantitation of nefazodone and its metabolites hydroxynefazodone m-chlorophenylpiperazine and triazole-dione in human plasma using single-ion monitoring.
Topics: Antidepressive Agents, Second-Generation; Chromatography, High Pressure Liquid; Humans; Mass Spectrometry; Piperazines; Reproducibility of Results; Sensitivity and Specificity; Triazoles | 1998 |
Brain-to-blood partition and in vivo inhibition of 5-hydroxytryptamine reuptake and quipazine-mediated behaviour of nefazodone and its main active metabolites in rodents.
Topics: Animals; Blood-Brain Barrier; Brain; Cerebral Cortex; Head Movements; Male; Mice; p-Chloroamphetamine; Piperazines; Prodrugs; Quipazine; Rats; Receptor, Serotonin, 5-HT2A; Receptors, Serotonin; Selective Serotonin Reuptake Inhibitors; Serotonin; Serotonin Agents; Serotonin Receptor Agonists; Triazoles | 1998 |
Nefazodone, meta-chlorophenylpiperazine, and their metabolites in vitro: cytochromes mediating transformation, and P450-3A4 inhibitory actions.
Topics: Alprazolam; Antidepressive Agents; Biotransformation; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Drug Interactions; Humans; Hydroxylation; Microsomes, Liver; Mixed Function Oxygenases; Piperazines; Triazoles | 1999 |
Simultaneous quantitation of d7-nefazodone, nefazodone, d7-hydroxynefazodone, hydroxynefazodone, m-chlorophenylpiperazine and triazole-dione in human plasma by liquid chromatographic-mass spectrometry.
Topics: Chromatography, High Pressure Liquid; Humans; Mass Spectrometry; Piperazines; Reference Standards; Reproducibility of Results; Sensitivity and Specificity; Triazoles | 2000 |
High-throughput quantitation of nefazodone and its metabolites in human plasma by high flow direct-injection LC-MS/MS.
Topics: Antidepressive Agents, Second-Generation; Chromatography, Liquid; Humans; Molecular Structure; Piperazines; Reference Standards; Reproducibility of Results; Sensitivity and Specificity; Spectrometry, Mass, Electrospray Ionization; Tandem Mass Spectrometry; Time Factors; Triazoles | 2007 |